Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study

BACKGROUND: Phosphodiesterase‐4 (PDE4) is a promising target in atopic dermatitis (AD) treatment. The pharmacokinetics (PK), safety, and efficacy of crisaborole topical ointment, 2% (formerly AN2728) (Anacor Pharmaceuticals, Palo Alto, CA), a boron‐based benzoxaborole PDE4 inhibitor, were evaluated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Dermatol
Main Authors: Zane, Lee T., Kircik, Leon, Call, Robert, Tschen, Eduardo, Draelos, Zoe Diana, Chanda, Sanjay, Van Syoc, Merrie, Hebert, Adelaide A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084761/
https://ncbi.nlm.nih.gov/pubmed/27193740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pde.12872
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados